The prevalence of GDM has been increasing over the past 8 years by 12% per year.
The prevalence of gestational diabetes mellitus (GDM) appears to be increasing in U.S. women, which may be a reflection of the well-documented obesity epidemic.
Dr. Dana Dabelea from the University of Colorado Health Sciences Center and colleagues examined temporal trends in GDM in more than 36,000 ethnically diverse women who were members of the Kaiser Permanente of Colorado health plan. All gave birth to a single infant between 1994 and 2002.
The prevalence of GDM among these women doubled over that period. "The prevalence of GDM has been increasing over the past 8 years" — by about 12% per year.
The increase, she said, was "present and similar" among all racial and ethnic groups studied. These included non-Hispanic whites, Hispanics, African Americans and Asians.
"Moreover, women born more recently were at increased risk for GDM compared with women born earlier, probably reflecting an increased exposure to risk factors operating before childbearing years, such as obesity," she said.
Dr. Dabelea pointed out that like type 2 diabetes mellitus and obesity, GDM is also increasing, "Future studies," she added, "need to explore reasons for this increase as well as the effects of this increase on the future generations."
Diabetes Care 2005;28:579-584.
DID YOU KNOW:
In A Specialist nurse-led clinic, to improve care and achieve the blood pressure targets achieved in the UK Prospective Diabetes Study, researchers conducted a specialist nurse-led intervention to treat and control hypertension and hyperlipidaemia in patients with diabetes. The Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes (SPLINT) trial enrolled 1,407 patients. An economic analysis showed that such a specialist nurse-led clinic as an adjunct to hospital-based diabetes care is effective and provides value for money. Diabetes Care,28 (40-46): Mason J, Freemantle N, Gibson J, New J Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial